HC Wainwright Has Bullish Outlook for BioLineRx Q3 Earnings

BioLineRx Ltd. (NASDAQ:BLRX) – HC Wainwright boosted their Q3 2024 EPS estimates for shares of BioLineRx in a report issued on Wednesday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of ($0.03) for the quarter, up from their previous forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for BioLineRx’s Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.04) EPS and FY2025 earnings at ($0.10) EPS.

Separately, StockNews.com initiated coverage on shares of BioLineRx in a research note on Friday. They set a “hold” rating on the stock.

BioLineRx Price Performance

BioLineRx stock opened at $0.44 on Friday. BioLineRx has a 12-month low of $0.39 and a 12-month high of $1.93. The stock has a market capitalization of $35.54 million, a P/E ratio of -0.99 and a beta of 1.48. The firm’s 50-day moving average is $0.53 and its two-hundred day moving average is $0.63. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. The firm had revenue of $5.39 million for the quarter, compared to analyst estimates of $3.93 million.

Institutional Investors Weigh In On BioLineRx

Several hedge funds have recently modified their holdings of the stock. Atria Investments Inc boosted its position in shares of BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares during the last quarter. PVG Asset Management Corp acquired a new stake in shares of BioLineRx in the second quarter worth approximately $70,000. Finally, CVI Holdings LLC acquired a new stake in shares of BioLineRx in the second quarter worth approximately $462,000. 1.56% of the stock is owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.